Fletcher Janine, Moody William E, Chowdhary Saqib, Coote John H
Department of Physiology, The Medical School, The University of Birmingham, Birmingham B15 2TT, UK.
Brain Res. 2006 Dec 6;1123(1):125-34. doi: 10.1016/j.brainres.2006.09.024. Epub 2006 Oct 24.
The neuronal isoform of the enzyme nitric oxide synthase (nNOS) has been identified in the caudal ventrolateral medulla of the rat close to the location of cardiac vagal motoneurones. Therefore in this study we tested identified ventral medulla cardioinhibitory sites for the involvement of nitric oxide (NO) in the baroreceptor-heart rate reflex pathway. In rats anaesthetised with a mixture of urethane (650 mg kg(-1)) and chloralose (50 mg kg(-1)) i.v., blood pressure and heart rate were monitored continuously and using stereotaxic coordinates the ventrolateral caudal brainstem within and around the nucleus ambiguus was systematically explored for sites producing a bradycardia of >50 bpm, without a change in blood pressure, using D,L homocysteic acid (DLH, 0.2 M) microinjections (50 nl) from a glass micropipette. Identified sites were marked with pontamine sky blue. Microinjection of the NO donor sodium nitroprusside (SNP, 1 mM, 50 nl) at a cardioinhibitory site also produced a significant bradycardia (68+/-14 bpm) while the NOS inhibitor N(G)-nitro-l-arginine (l-NNA) (3 mM, 50 nl) caused a small significant increase in heart rate (5+/-1 bpm). Baroreceptor reflex gain measured by the response in heart rate to a change in blood pressure induced by phenylephrine i.v. was significantly increased (610+/-171%, p<0.05) during the steady state of the response to SNP, whereas it was significantly reduced (73+/-5%, p<0.01) by l-NNA injection at a medullary cardioinhibitory site. An inhibitor of soluble guanylyl cyclase, (1)H-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one (ODQ, 1 mM, 50 nl) also significantly reduced the baroreceptor reflex gain (63+/-8%, p<0.05). The results suggest that a NOS-cGMP signalling system in the baroreceptor reflex pathway distal to the NTS and closer to cardiac vagal motoneurones in the caudal ventral medulla contributes to enhancement of cardiac vagal tone.
一氧化氮合酶(nNOS)的神经元亚型已在大鼠延髓尾端腹外侧被鉴定出来,其位置靠近心迷走运动神经元。因此,在本研究中,我们检测了延髓腹侧已确定的心脏抑制位点,以确定一氧化氮(NO)是否参与压力感受器 - 心率反射通路。在用静脉注射乌拉坦(650 mg kg⁻¹)和氯醛糖(50 mg kg⁻¹)混合麻醉的大鼠中,连续监测血压和心率,并使用立体定位坐标,系统地探索疑核内及周围的延髓尾端腹外侧,寻找能使心率减慢>50次/分钟且血压无变化的位点,方法是从玻璃微量移液器微量注射D,L - 高半胱氨酸(DLH,0.2 M,50 nl)。已确定的位点用滂胺天蓝标记。在一个心脏抑制位点微量注射NO供体硝普钠(SNP,1 mM,50 nl)也会产生显著的心动过缓(68±14次/分钟),而NOS抑制剂N⁺-硝基-L-精氨酸(L-NNA)(3 mM,50 nl)会使心率小幅显著增加(5±1次/分钟)。通过静脉注射去氧肾上腺素诱导血压变化时心率的反应来测量的压力感受器反射增益,在对SNP反应的稳态期间显著增加(610±171%,p<0.05),而在延髓心脏抑制位点注射L-NNA后则显著降低(73±5%,p<0.01)。可溶性鸟苷酸环化酶抑制剂(1)H-(1,2,4)恶二唑并(4,3-a)喹喔啉-1-酮(ODQ,1 mM,50 nl)也显著降低了压力感受器反射增益(63±8%,p<0.05)。结果表明,在压力感受器反射通路中,位于孤束核远端且更靠近延髓尾端腹侧心迷走运动神经元的NOS - cGMP信号系统有助于增强心迷走神经张力。